Integrative Multiomics Profiling Reveals Immune Determinants of Response to Disitamab Vedotin Plus Penpulimab in HER2-Low Breast Cancer.

Authors

Xiaoxiao Liu, Yuting Song, Lei Liu, Aaron Qi Zhang, Xin Xie, Bing Wei, Ping He, Chunying Zhuang, Juanjuan Li, Xi Yan, Tinglun Tian, Xiaorong Zhong, Jie Chen, Yan Cheng, Dan Zheng, Shibao Li, Hao Wang, Ting Luo

Published in

MedComm. Volume 7. Issue 10. Pages e70988. Epub Oct 04, 2026.

Abstract

This prospective single-arm study evaluated neoadjuvant disitamab vedotin plus penpulimab in Stage II-III HER2-low breast cancer (immunohistochemistry 1+ or 2+, fluorescence in situ hybridization-negative), a population lacking targeted neoadjuvant options. Twenty patients received the combination every 3 weeks for six cycles before surgery. In the intention-to-treat population, the pathologic complete response (pCR) was 20.0% (four out of 20; 95% CI, 5.7-43.7%), and the objective response rate (ORR) was 45.0% (nine out of 20; 95% CI, 23.1-68.5%). Among 16 patients who completed protocol-defined treatment and surgery, pCR was 25.0% (four out of 16; 95% CI, 7.3-52.4%), ORR was 56.3% (nine out of 16; 95% CI, 29.9-80.2%), and 31.3% achieved residual cancer burden Class 0-1. Grade ≥3 adverse events occurred in 25.0%; no treatment-related deaths occurred. pCR-associated tumors had a pretreatment immune-active microenvironment enriched in inflammatory proteins, transcripts, and tumor-infiltrating lymphocytes, whereas nonresponders displayed a higher M2/M1 macrophage ratio. An exploratory baseline score combining CCL19 and the M2/M1 ratio showed pCR/non-pCR separation (AUC = 0.8889) but attenuated on internal validation (LOOCV AUC = 0.6667, optimism-corrected bootstrap AUC = 0.8375). This combination showed preliminary antitumor activity with manageable safety; however, given the small sample size and wide confidence intervals, these findings preclude definitive conclusions about efficacy and warrant validation in larger randomized controlled trials.

PMID:
42830862
Bibliographic data and abstract were imported from PubMed on 05 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.